Stay updated on Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial
Sign up to get notified when there's something new on the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page.

Latest updates to the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check26 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check63 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a Phase 1b clinical trial for XMT-1522, which included eligibility criteria and study design. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference36%
Stay in the know with updates to Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page.